via its unique targeting of Vγ9Vδ2 T cells and tumor associated antigens (TAAs).
Gammabody™ platform approach is fully modular, allowing for usage of Fc and existing antibodies
‘Off the shelf’ manufacturing
They combine a variety of traits to accomplish this including:
High potency with EC50s in low picomolar range
Potential for expansion of activated Vγ9Vδ2 T cells
Avoids the detrimental co-activation of immune-suppressive cells, such as Tregs
Secretion of pro-inflammatory cytokines that attract and activate other cells within the immune system
Antigen presenting capability, potentially triggering an adaptive immune reaction, enabling deep and durable responses
LAVA’s Gammabody™ platform acts through multiple mechanisms to induce selective, potent killing of tumor cells
Proof of principle of LAVA’s Gammabody™ approach has been established by in vitro, in vivo and ex vivo studies which demonstrate potent cell death in both tumor cell lines and patient-derived cells in both solid tumors and hematologic malignancies. Based on this data, LAVA is advancing several Gammabody™ drug candidates towards clinical development.